Search Result

Pathways Recommended:	Stem Cell/Wnt Cell Cycle/DNA Damage

Results for "

basal cell carcinoma,

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (1) Endogenous Metabolite (1) HDAC (1) Hedgehog (1) JAK (2) Protease Activated Receptor (PAR) (1) Syk (2)
By Research Areas:	Cancer (7) Inflammation/Immunology (2)

Inhibitors & Agonists

Screening Libraries

Peptides

MCE Kits

Natural
Products

Targets Recommended: Itk TOPK NAMPT ALCAM/CD166 GDNF Receptor BCL6 Tim3

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-107408

SANT 2	Hedgehog	Cancer
SANT 2 is a potent antagonist of Hh-signaling pathway. Hedgehog (Hh) signaling plays an important role in cell signaling of embryonic development and adult tissue homeostasis. SANT 2 has the potential for the research of several malignancies including Gorlin syndrome (a disorder predisposing to basal cell carcinoma, medulloblastoma and rhabdomyosarcoma), prostate, pancreatic and breast cancers .

HY-157528

CJ28	Endogenous Metabolite	Cancer
CJ28 is a cortisol biosynthesis inhibitor that significantly inhibits basal and stimulated cortisol production in human adrenal carcinoma cell lines. CJ28 exhibits inhibitory effects by reducing steroidogenesis and de novo cholesterol biosynthesis .

HY-142684

Pyruvate Carboxylase-IN-1	Others	Cancer
Pyruvate Carboxylase-IN-1 (compound 37) is a potent inhibitor of pyruvate carboxylase (PC) with IC₅₀s of 0.204 and 0.104 μM in cell lysate-based and cell-based PC activity, respectively. Pyruvate Carboxylase-IN-1 is a natural analog of erianin. Pyruvate Carboxylase-IN-1 inhibites the enzymatic activity of PC, mediating the anticancer effect in human hepatocellular carcinoma (HCC) .

HY-142685

Pyruvate Carboxylase-IN-2	Others	Cancer
Pyruvate Carboxylase-IN-2 (compound 29) is a potent inhibitor of pyruvate carboxylase (PC) with IC₅₀s of 0.065 and 0.097 μM in cell lysate-based and cell-based PC activity, respectively. Pyruvate Carboxylase-IN-2 is a natural analog of erianin. Pyruvate Carboxylase-IN-2 inhibites the enzymatic activity of PC, mediating the anticancer effect in human hepatocellular carcinoma (HCC) .

HY-10226

JNJ-16241199 R306465	Apoptosis HDAC	Cancer
JNJ-16241199 is an orally active, selective *hydroxamate-based* histone deacetylase (HDAC) inhibitor, with the IC₅₀ of 3.3 nM and 23 nM for HDAC1 and HDAC8*, respectively. JNJ-16241199 induces histone 3 acetylation and strongly increases the expression of p21 ^waf1, ^cip1 in A2780 ovarian carcinoma* cells. JNJ-16241199 induces cell apoptosis and shows anticancer activity in a broad spectrum of human malignancies. JNJ-16241199 can be used for cancer study .

HY-103018

Gusacitinib 1 Publications Verification ASN-002	JAK Syk	Inflammation/Immunology Cancer
Gusacitinib (ASN-002) is an orally active dual SYK/JAK kinase inhibitor with IC₅₀ values of 5, 46, 4, 11 and 8 nM for SYK, JAK1, JAK2, JAK3 and TYK2, respectively. Gusacitinib rapidly and significantly suppressed key inflammatory pathways implicated in atopic dermatitis pathogenesis. Gusacitinib can be used in the research of chronic hand eczema and cancers such as basal cell carcinoma .

HY-103018A

Gusacitinib hydrochloride ASN-002 hydrochloride	JAK Syk	Inflammation/Immunology Cancer
Gusacitinib (ASN-002) hydrochloride is an orally active dual SYK/JAK kinase inhibitor with IC₅₀ values of 5, 46, 4, 11 and 8 nM for SYK, JAK1, JAK2, JAK3 and TYK2, respectively. Gusacitinib hydrochloride rapidly and significantly suppressed key inflammatory pathways implicated in atopic dermatitis pathogenesis. Gusacitinib hydrochloride can be used in the research of chronic hand eczema and cancers such as basal cell carcinoma .

HY-P5372

Ala-parafluoroPhe-Arg-Cha-Cit-Tyr-NH2	Protease Activated Receptor (PAR)	Others
Ala-parafluoroPhe-Arg-Cha-Cit-Tyr-NH2 is a biological active peptide. (Protease activated receptor 1 (PAR-1) belongs to a subfamily of G-protein coupled receptors and is known to mediate the cellular effects of thrombin. This peptide is a PAR-1 selective agonist displaying a high level of specificity to PAR-1 over PAR-2. The specificity of peptide was evaluated in cell-based calcium signaling assay using HEK293 cells. PAR-1 selective agonists can be used to study PAR-1 activation in vivo. In addition to its varied cellular effects of thrombin, PAR-1 has also been shown to coordinate with PAR-4 and regulate thrombin-induced hepatocellular carcinoma harboring thrombin formation within the tumor environment classified as 'coagulation type'.)

Cat. No.	Product Name

HY-L148

TCA Cycle Compound Library	65 compounds
The TCA cycle (tricarboxylic acid cycle)—is also known as the Krebs cycle or the citric acid cycle (CAC). The TCA cycle is a series of chemical reactions that release stored energy through the oxidation of acetyl-CoA in carbohydrates, fats, and proteins. For decades, the TCA cycle has been considered as the central pathway for cell oxidative phosphorylation to produce energy and biosynthesis. Research shows that TCA cycle is associated with many diseases, especially cancer. In colon carcinoma, liver cancer and other cancers, there are mutations that lead to the imbalance of TCA cycle metabolites, indicating that TCA cycle may be related to the occurrence of cancer. Understanding the role and molecular mechanism of TCA cycle in inhibiting or promoting cancer progression will promote the development of new metabolite-based cancer treatment methods in the future. MCE supplies a unique collection of 65 compounds related to the TCA cycle. MCE TCA Cycle Compound Library is a useful tool for the TCA cycle related research and anti-cancer drug development.

TCA Cycle Compound Library

65 compounds

The TCA cycle (tricarboxylic acid cycle)—is also known as the Krebs cycle or the citric acid cycle (CAC). The TCA cycle is a series of chemical reactions that release stored energy through the oxidation of acetyl-CoA in carbohydrates, fats, and proteins.

For decades, the TCA cycle has been considered as the central pathway for cell oxidative phosphorylation to produce energy and biosynthesis. Research shows that TCA cycle is associated with many diseases, especially cancer. In colon carcinoma, liver cancer and other cancers, there are mutations that lead to the imbalance of TCA cycle metabolites, indicating that TCA cycle may be related to the occurrence of cancer. Understanding the role and molecular mechanism of TCA cycle in inhibiting or promoting cancer progression will promote the development of new metabolite-based cancer treatment methods in the future.

MCE supplies a unique collection of 65 compounds related to the TCA cycle. MCE TCA Cycle Compound Library is a useful tool for the TCA cycle related research and anti-cancer drug development.

Cat. No.	Product Name	Target	Research Area

HY-P5372

Ala-parafluoroPhe-Arg-Cha-Cit-Tyr-NH2	Protease Activated Receptor (PAR)	Others
Ala-parafluoroPhe-Arg-Cha-Cit-Tyr-NH2 is a biological active peptide. (Protease activated receptor 1 (PAR-1) belongs to a subfamily of G-protein coupled receptors and is known to mediate the cellular effects of thrombin. This peptide is a PAR-1 selective agonist displaying a high level of specificity to PAR-1 over PAR-2. The specificity of peptide was evaluated in cell-based calcium signaling assay using HEK293 cells. PAR-1 selective agonists can be used to study PAR-1 activation in vivo. In addition to its varied cellular effects of thrombin, PAR-1 has also been shown to coordinate with PAR-4 and regulate thrombin-induced hepatocellular carcinoma harboring thrombin formation within the tumor environment classified as 'coagulation type'.)

Cat. No.	Product Name

HY-K6111

Human Head and Neck Squamous Cell Carcinoma Organoid Kit
MCE Human Head and Neck Squamous Cell Carcinoma Organoid Kit contains Head and Neck Squamous Cell Carcinoma Organoid Basal Medium A, Head and Neck Squamous Cell Carcinoma Organoid Supplement B (50x), Head and Neck Squamous Cell Carcinoma Organoid Supplement C (250x). This product can be used to efficiently construct human head and neck squamous cell carcinoma organoid.

CJ28	Structural Classification Natural Products Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields Cancer	Endogenous Metabolite
CJ28 is a cortisol biosynthesis inhibitor that significantly inhibits basal and stimulated cortisol production in human adrenal carcinoma cell lines. CJ28 exhibits inhibitory effects by reducing steroidogenesis and de novo cholesterol biosynthesis .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks